CPRX
Catalyst Pharmaceuticals, Inc.
Healthcare · Biotechnology · NCM

$31.32
Close 2026-05-28
✓ ETHICAL PASS

UNKNOWN MOAT

HIGH
Data Confidence: 100%
Full financial profile available

Market Cap
$3.8B
Trailing P/E
18.10
Forward P/E
9.99
Rev Growth
+5.6%
Profit Margin
37.1%
ROE
24.5%
Analyst Target
$32.00
Recommendation
NONE

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Ethical Screen
Business Activity PASS
Debt Ratio N/A
Cash Ratio N/A
Receivables Ratio N/A
Revenue Ratio (0.00%) PASS
Overall PASS
Score Ethical: 64.7
Score Valuation: 78.5
Score Quality: 75.2
Score Combined: 61.9

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership

Opportunity Scores
Valuation100.0
Quality88.2
Cash Flow56.0
Moat40.0
Balance Sheet97.2
Debt Purity50.0
Liquid Purity50.0
Rev Purity100.0
Compliance100.0
Tier: SILVER · Score: 61.7 · Rank: #448

Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.

Additional Fundamentals
Enterprise Value
$3.1B
Price/Book
3.78
Beta
0.718
Analysts
5
Total Revenue (TTM)
$597.0M
Total Debt
$2.7M
Earnings Growth
+11.1%
Short Ratio
2.28
Short % Float
0.1%
Employees
182

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite

Trade Consideration

The Opportunity
Score 61.9 (P97 — top 2.9% of scored tickers). Unknown Moat. Ethical PASS. 5 analysts at None.
Price: $31.32 | Target: $32.60 (+4%)

Score
62

Moat
Unknown

Conviction
Standard

Upside
+4%

The Fundamentals
Revenue Growth+5.6%
Profit Margin37.1%
ROE24.5%
Forward P/E10.0
Market Cap$3.8B

Position Sizing Scenarios
Stop: $26.62 (-15%) | Entry: $31.32
Shares Cost Profit to Target R:R
To Consensus ($32.60, 5 analysts)
10 $313.20 +$12.80 (4%) 0.3R
50 $1,566.00 +$64.00 (4%) 0.3R
100 $3,132.00 +$128.00 (4%) 0.3R
Risk Factors
  • No elevated risk flags in current data

The Verdict
Catalyst Pharmaceuticals, Inc. passes all ethical screens and holds a unknown competitive moat.

Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

B
Quant Score
69.3
Risk Grade
LOW_RISK
Layers
7

Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-3.4%
worst expected daily loss, 19 in 20 days
CVaR 95%
-4.8%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
1.47
above 1.0 is good
Max Drawdown
-27.3%
Worst Day

Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
90
Liquidity Grade
HIGHLY LIQUID

Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal

Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
ABOVE_200
Bollinger Position
UPPER_HALF
Beta
Relative Volume
0.7x
Short Interest

Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone

Piotroski F-Score

Earnings Beat Rate
Earnings Consistency

Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
Ticker Correlation
IWM 0.449
SANA 0.430
HQH 0.423
VIR 0.419
VTI 0.411
Inverse Correlated
Ticker Correlation
ZHCD.QA -0.141
4326.SR -0.137
0066.HK -0.133
AGILQ -0.129
0002.HK -0.128

Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Wednesday
Worst Day
Thursday
Best Month
Oct
Worst Month
Jun
Fri-Mon Effect
-0.08978573978933618

Momentum Rankings

How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
+6.3%
3M Return
+25.8%
6M Return
+33.1%
12M Return
+26.0%
Momentum Rank
#883
Momentum Signal
UP

Related Tickers

Similar in Healthcare

INCY — Incyte CRMD — CorMedix Inc. ✓ UHS — Universal Health Services ✓ FENC — Fennec Pharmaceuticals Inc. ✓ REGN — Regeneron Pharmaceuticals ✓

Also in TE500

NEM — Newmont ✓ NU — Nu Holdings Ltd. PTC — PTC Inc. ✓ SBNY — Signature Bank EXE — Expand Energy ✓
Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry Indicators Options Calendar Composites Boycott Tracker Convergence Screener Fed Tracker Explore All Is It Halal? Earnings Calendar Dividend Screener Country Guides Glossary Join Free →

Get our weekly market brief free.